Gelonghui, July 4 | According to the Guangfa Securities Research Report, Hengrui Pharmaceutical (600276.SH)'s application for bupivacaine liposome marketing was approved by the FDA. This is the first generic drug approved in the US since the original product was marketed in the US in 2011. Bupivacaine liposomes use advanced polycystic liposome delivery technology to achieve long-term analgesia through slow release and effectively improve patients' quality of life. Global sales of bupivacaine liposomes reached 0.538 billion US dollars in 2023, which has large market space and a good competitive pattern. The company's innovation ushered in a good harvest, and the internationalization process accelerated. Considering the company's leading position in the domestic pharmaceutical industry, referring to comparable company valuations, the company was given 60 times PE valuation in 2024, corresponding to a reasonable value of 50.48 yuan/share, maintaining a “buy” rating.
研报掘金丨广发证券：恒瑞医药布比卡因脂质体在美获批，维持“买入”评级
Research reports | GF SEC: Jiangsu Hengrui Pharmaceuticals' Bupivacaine Liposome Obtains Approval in the United States, Maintain "Buy" Rating
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.